Welcome to our dedicated page for Inflection Point Acquisition IV SEC filings (Ticker: BACQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inflection Point Acquisition Corp. IV (BACQ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed blank check company. Inflection Point Acquisition Corp. IV, a Cayman Islands exempted company and emerging growth company, files current and periodic reports with the U.S. Securities and Exchange Commission that describe its capital structure, governance and proposed business combination activities.
Among the key documents available are multiple Forms 8-K detailing material events. A filing dated September 23, 2025 describes the Business Combination Agreement between Bleichroeder Acquisition Corp. I (which will be renamed Inflection Point Acquisition Corp. IV), a merger subsidiary and Merlin Labs, Inc., a developer of assured, autonomous flight technology for defense customers. This 8-K also discusses a strategic partnership between Merlin Labs and GE Aerospace and notes that Inflection Point Acquisition Corp. IV and Merlin Labs are contemplating additional private placement financing in connection with the business combination.
An 8-K dated October 21, 2025 reports shareholder approval of changing the company’s name to Inflection Point Acquisition Corp. IV and amending its articles to modify redemption timing for public shares. Another 8-K dated November 17, 2025 outlines amendments to a Securities Purchase Agreement and additional securities purchase agreements that increase PIPE commitments for preferred stock and warrants to be issued by New Merlin Labs in connection with the transaction.
Through this filings page, users can review these 8-Ks, the definitive proxy statement on Schedule 14A regarding the name change and article amendments, and future registration statements on Form S-4 related to the proposed business combination. Stock Titan enhances this access with AI-powered summaries that highlight the main terms of the business combination, changes to shareholder rights, and details of PIPE and pre-funded note financings, helping readers interpret BACQ’s SPAC-related disclosures more efficiently.
Barclays PLC reported beneficial ownership of 1,755,135 shares of Bleichroeder Acquisition Corp common stock, representing 6.90% of the class as of the event dated 12/31/2025. Barclays has sole voting and sole dispositive power over all these shares and no shared voting or dispositive power.
The position is reported on a Schedule 13G, indicating the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company. Subsidiaries identified in connection with this holding include Barclays Bank PLC and Barclays Capital Inc.
AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC report beneficial ownership of 920,621 Class A ordinary shares of Inflection Point Acquisition Corp. IV, equal to 3.62% of the class as of the stated event date.
All three AQR entities report shared voting and dispositive power over these shares and no sole voting or dispositive power. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Inflection Point Acquisition Corp. IV and co-registrant Merlin Labs, Inc. filed Amendment No. 2 to their Form S-4 registration statement. This amendment is an exhibits-only update, filed solely to provide an updated legal opinion (Exhibit 5.1) and related consent (Exhibit 23.1).
All securities covered by the registration will be issued by Inflection Point Acquisition Corp. IV after it domesticates into Delaware and is renamed “Merlin, Inc.” following the planned transactions described in the proxy statement/prospectus. The underlying business combination agreement and related governance, lock-up, incentive plan and consent documents remain as previously filed.
Inflection Point Acquisition Corp. IV filed an amended S-4 to register up to 164,748,772 shares of New Merlin Common Stock, 10,288,021 shares of Series A Preferred Stock, Series A warrants and related rights/units in connection with its proposed business combination with Merlin Labs, Inc.
The deal will domesticate Inflection Point from the Cayman Islands to Delaware as “Merlin, Inc.” and merge its subsidiary with Merlin, leaving Merlin as a wholly owned operating subsidiary. Merlin equity holders will receive New Merlin Common Stock based on an $800,000,000 purchase price divided by the SPAC share redemption price.
The transaction is supported by multiple financing arrangements, including approximately $87.3 million of pre-funded convertible notes and warrants issued by Merlin and up to $120 million of Series A Preferred Stock PIPE investments with attached New Merlin Series A Warrants. Inflection Point public shareholders can redeem their shares for cash (about $10.52 per share as of the record date) and are being asked to approve the merger, domestication, charter/bylaw changes, share issuances, equity plans, board slate and potential meeting adjournment.
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC have filed an initial ownership report for Inflection Point Acquisition Corp. IV (BACQ), showing indirect beneficial ownership of 2,768,921 shares of Class A common stock as of November 26, 2025.
The shares are held directly by Goldman Sachs and indirectly by GS Group, with each reporting person disclaiming beneficial ownership except to the extent of its pecuniary interest. This filing reflects that their stake increased to above 10% of the company’s outstanding Class A common stock, making them 10% owners.
Inflection Point Acquisition Corp. IV filed a Form S-4 to register 163,582,614 shares of New Merlin Common Stock and related preferred stock, warrants, rights and units for its proposed business combination with Merlin Labs, Inc., after domestication to Delaware as “Merlin, Inc.”
The proxy statement/prospectus also covers up to 10,288,021 shares of 12.0% Series A Cumulative Convertible Preferred Stock, New Merlin Series A Warrants initially exercisable for up to 10,103,376 shares of common stock, 25,425,000 Post-Domestication Rights and 653,821 Post-Domestication Units. The merger consideration is based on an $800,000,000 Purchase Price, delivered in New Merlin equity, with additional capital from approximately $87.3 million of pre-funded convertible notes and $120 million of Series A Preferred PIPE investments.
Inflection Point shareholders will vote at an extraordinary general meeting on the business combination, domestication, new charter and bylaws, equity plans, director elections and share issuance approvals, and Public Shareholders may elect to redeem their Public Shares for cash. The Sponsor and Inflection Point Fund, which together hold a significant stake and will receive substantial New Merlin equity and Series A Preferred Stock upon closing, have agreed to vote in favor of all proposals, creating potential conflicts of interest and dilution for non-redeeming Public Shareholders.
Inflection Point Acquisition Corp. IV plans a proposed business combination valued at about $1 billion with Merlin Labs Inc., a U.S.-based developer of takeoff-to-touchdown autonomy for aircraft. Merlin’s aircraft-agnostic, AI-powered software is used in both military and civil aviation programs and has been proven through hundreds of autonomous flights at test facilities worldwide. The company highlights more than $100M in total awarded contracts from military customers as it works to address national security needs with safe, reliable autonomy.
The communication stresses that many of the statements are forward-looking and subject to significant risks and uncertainties, including the possibility that the transaction may not close, shareholder redemptions, regulatory and legal outcomes, and execution challenges for Merlin’s growth plans. Inflection Point expects to file a Form S-4 registration statement containing a proxy statement/prospectus, and shareholders are advised that this will include important information before they vote on the business combination.
Inflection Point Acquisition Corp. IV (BACQ) filed a communication featuring a Merlin Labs press release announcing several senior hires as the company prepares to go public through a business combination with BACQ. Merlin named Leslie Ravestein as Chief Legal Officer, David Lasater as Chief People Officer, and Pablo Gonzalez as Senior Vice President of Engineering. The new leaders are tasked with strengthening legal and compliance functions, talent strategy, and engineering execution ahead of Merlin’s planned public listing next year.
Merlin develops assured, autonomous flight technology for defense and civil aviation and reports having $100M+ in total awarded contracts from military customers. The communication also includes standard forward-looking statement disclosures and explains that a Form S-4 registration statement and proxy statement/prospectus will be filed for shareholder approval of the proposed business combination.
Inflection Point Acquisition Corp. IV highlighted that aviation autonomy company Merlin has upsized its private investment in public equity (PIPE) financing to more than $200 million ahead of their planned business combination and public listing. Merlin initially secured $125 million in committed PIPE capital at an $800 million pre-money valuation, led by Inflection Point Asset Management, and has now added over $75 million, including $100 million from Inflection Point. Merlin plans to use the added capital to strengthen its balance sheet at closing, expand U.S. defense programs and aircraft integrations, pursue acquisitions, and increase hiring. The company develops AI-powered flight autonomy software and reports an estimated $3 billion identified revenue pipeline, citing awarded military contracts and ambitions to scale across transport, tanker, turboprop, and future uncrewed and collaborative combat aircraft.
Inflection Point Acquisition Corp. IV announced a significant expansion of its private investment in public equity for the proposed business combination with Merlin Labs. The lead investor increased its commitment from $50,000,000 to $100,000,000, for 9,803,922 shares of 12.0% Series A Cumulative Convertible Preferred Stock and a matching warrant package at Closing. Additional accredited investors agreed to buy 1,666,668 more preferred shares with related warrants in a separate private placement on substantially the same terms. Merlin Labs also sold an additional Pre-Funded Convertible Note with approximately $10,900,000 principal for about $9,300,000, adding to roughly $55,000,000 of similar notes previously issued. These securities are being sold in unregistered offerings relying on Section 4(a)(2), and the overall deal remains subject to shareholder approval and completion of the business combination.